Ravi Juluri, MD
Internal Medicine · Avon, INNPI 1457523151
Payments from drug & device makers
Across 719 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Johnson & Johnson$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Regeneron Healthcare Solutions, Inc.$620
- Janssen Scientific Affairs, LLC$598
- plus $4K from 29 others
What the payments were for
- Food & beverage$13,96999%
- Education$1151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 241 | $4,530 |
| Takeda Pharmaceuticals U.S.A., Inc. | 110 | $1,618 |
| Johnson & Johnson | 75 | $1,332 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 62 | $1,116 |
| Regeneron Healthcare Solutions, Inc. | 36 | $620 |
| Janssen Scientific Affairs, LLC | 5 | $598 |
| Gilead | 28 | $468 |
| Bristol Myers Squibb | 19 | $418 |
| Sanofi | 23 | $416 |
| Madrigal Pharmaceuticals | 7 | $306 |
| QOL Medical, LLC | 12 | $283 |
| Ardelyx, Inc. | 10 | $270 |
| Ironwood Pharmaceuticals, Inc | 17 | $264 |
| E.r. Squibb & Sons, L.L.C. | 2 | $237 |
| Lilly USA, LLC | 10 | $214 |
| Phathom Pharmaceuticals, Inc. | 4 | $157 |
| Celltrion USA Inc. | 7 | $142 |
| Redhill Biopharma Inc. | 2 | $138 |
| Aimmune Therapeutics, Inc. | 2 | $137 |
| Nestle Healthcare Nutrition Inc. | 7 | $136 |
| Pfizer | 8 | $134 |
| Organon | 5 | $73 |
| Ferring Pharmaceuticals Inc. | 4 | $71 |
| Daiichi Sankyo Inc. | 4 | $66 |
| UCB, Inc. | 3 | $53 |
| Pharmacosmos Therapeutics Inc. | 2 | $52 |
| Merck | 3 | $45 |
| Intercept Pharmaceuticals, Inc. | 3 | $44 |
| Fresenius Kabi USA, LLC | 2 | $32 |
| Boston Scientific | 1 | $24 |
| Novo Nordisk | 1 | $24 |
| Evoke Pharma, Inc. | 1 | $21 |
| Tersera Therapeutics LLC | 1 | $18 |
| Boehringer Ingelheim | 1 | $14 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,084 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 11 | $41,834 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 56 | $3,333 |
| Sucralfate | 13 | $2,455 |
| Mesalamine DrMesalamine | 12 | $2,287 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 12 | $1,932 |
| Pantoprazole Sodium | 147 | $1,202 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 49 | $685 |
| Esomeprazole Magnesium | 11 | $486 |
| Dicyclomine Hcl | 23 | $441 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 21 | $391 |
| Omeprazole | 44 | $383 |
| Famotidine | 35 | $313 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 16 | $233 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 11 | $129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,116 | $41,83411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Avon
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
- Rita SchmidSouth Bend$599K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.